CURE.X Stock Overview
Together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Biocure Technology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.06 |
| 52 Week High | CA$0.32 |
| 52 Week Low | CA$0.045 |
| Beta | 2.65 |
| 11 Month Change | -55.56% |
| 3 Month Change | -55.56% |
| 1 Year Change | n/a |
| 33 Year Change | -95.83% |
| 5 Year Change | -96.97% |
| Change since IPO | -98.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| CURE.X | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 2.2% |
| 1Y | n/a | 11.6% | 24.3% |
Return vs Industry: Insufficient data to determine how CURE.X performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how CURE.X performed against the Canadian Market.
Price Volatility
| CURE.X volatility | |
|---|---|
| CURE.X Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: CURE.X's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine CURE.X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Simon Cheng | www.biocuretech.com |
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells.
Biocure Technology Inc. Fundamentals Summary
| CURE.X fundamental statistics | |
|---|---|
| Market cap | CA$626.67k |
| Earnings (TTM) | -CA$4.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs CURE.X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURE.X income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.13m |
| Earnings | -CA$4.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.9% |
How did CURE.X perform over the long term?
See historical performance and comparison